Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial

Paul F. Schellhammer; Gerald W. Chodak; James B. Whitmore; Robert B. Sims; Mark W. Frohlich; Philip W. Kantoff

doi:10.1016/j.urology.2013.01.061

Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial

著者: Paul F. Schellhammer, Gerald W. Chodak, James B. Whitmore, Robert B. Sims, Mark W. Frohlich, Philip W. Kantoff - Urology 2013 被引用: 242

Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial | Litlas